Descriptive Study of the Incidence of Malignancy in Patients with Severe Asthma Overall and Among Those Receiving Benralizumab and Other Therapies, a Post Authorization Safety Study

14/11/2018
07/05/2025
EU PAS number:
EUPAS26310
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

D3250R00042-pass-csp-v4_Redacted

English (391.09 KB - PDF) View document
Updated protocol

D3250R00042 - Protocol v.5_Redacted

First published: 22/02/2024
English (373.74 KB - PDF) View document
Study results
Study report
Study report

D3250R00042 - Protocol v.2_Redacted

English (629 KB - PDF) View document

D3250R00042 - Protocol v.3_Redacted

English (3.23 MB - PDF) View document

D3250R00042 EUPAS26310-PASS-Interim study report_Redacted

English (844.24 KB - PDF) View document

D3250R00042- Second Interim Study Report_Redacted

English (7.37 MB - PDF) View document

D3250R00042-protocol-v1_Redacted

English (527.12 KB - PDF) View document

EUPAS26310_Malignancy PASS_ Third Interim Report_Redacted.pdf

English (981.69 KB - PDF) View document

Malignancy PASS Final CSR Synopsis (EUPAS26310_NCT04991805).pdf

English (202.06 KB - PDF) View document
Other information
Study, other information

D3250R00042 - Protocol v.2_Redacted.pdf

English (629 KB - PDF) View document

D3250R00042 - Protocol v.3_Redacted.pdf

English (3.23 MB - PDF) View document

D3250R00042 EUPAS26310-PASS-Interim study report_Redacted.pdf

English (844.24 KB - PDF) View document

D3250R00042-protocol-v1_Redacted.pdf

English (527.12 KB - PDF) View document